BOEHRINGER-INGELHEIM
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk.1 The findings were reported today at the American Diabetes Association’s 79th Scientific Sessions in San Francisco.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190610005823/en/
The trial met its primary endpoint, defined as non-inferiority for linagliptin versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE), which occurred in 11.8 percent (356 people) of the linagliptin group compared to 12.0 percent (362 people) of the glimepiride group.1 The overall safety profile of linagliptin in CAROLINA® was consistent with previous data, and no new safety signals were observed.1,2
The study assessed linagliptin safety over the longest period ever studied in a DPP-4 inhibitor cardiovascular outcome trial, with a median follow-up of more than 6 years.1 Linagliptin was similar to glimepiride in the secondary endpoint of 3P-MACE plus hospitalisation for unstable angina (4P-MACE - 13.2 percent for linagliptin versus 13.3 percent for glimepiride).1
In CAROLINA® , a higher proportion of patients within the linagliptin group (16.0 percent) achieved the secondary composite efficacy endpoint of treatment sustainability versus the glimepiride group (10.2 percent).*1 Compared with glimepiride, linagliptin demonstrated similar overall effects on HbA1c, but significantly reduced the relative risk for hypoglycaemia (low blood sugar) by 77 percent (10.6 percent of patients treated with linagliptin experienced any hypoglycaemic incident versus 37.7 percent for glimepiride).1 This risk reduction was consistent and significant across all hypoglycaemia categories, including severe hypoglycaemia and those requiring hospitalisation. Linagliptin was also associated with a modest weight reduction of 1.5 kg versus glimepiride.1
“CAROLINA® is unique in that it is the only DPP-4 inhibitor cardiovascular outcome trial with an active comparator,” said Waheed Jamal, MD, Corporate Vice President and Head of Cardiovascular & Metabolic Medicine, Boehringer Ingelheim. “When additional glucose-lowering is needed, DPP-4 inhibitors and sulfonylureas continue to be frequently used as add-on therapies to metformin. These data can further support physicians in choosing the most appropriate glucose-lowering treatment for each individual patient.”
“The American Diabetes Association and European Association for the Study of Diabetes recommend type 2 diabetes treatments with proven cardiovascular benefits for patients with established cardiovascular disease,” said Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Lilly Diabetes. “But, physicians considering additional therapies to lower blood glucose for their patients need a DPP-4 inhibitor with an established long-term safety profile. These new data from CAROLINA® , along with data from the placebo-controlled cardiovascular outcome trial CARMELINA® , expand the evidence and experience with linagliptin, to provide healthcare professionals with confidence in the long-term safety profile across a broad range of patients with type 2 diabetes.”
About CAROLINA
®
CAROLINA®
(CARdiovascular Outcome study of LINAgliptin versus glimepiride in
patients with type 2 diabetes) is a multi-national, randomised,
double-blind, active-controlled clinical trial that involved 6,033
adults with type 2 diabetes from 43 countries at more than 600 sites
observed for a median duration of more than 6 years.3,4
The
trial included adults with early type 2 diabetes: adults with a median
disease duration of 6.2 years, who either received no treatment at all,
or received 1-2 glucose lowering agents (e.g. metformin).4
It
was designed to assess the effect of Trajenta®
(linagliptin)
(5 mg once daily) compared to the sulphonylurea glimepiride (both added
to stable background glucose-lowering medication and cardiovascular
standard of care) on cardiovascular safety in adults with type 2
diabetes and increased cardiovascular risk or established cardiovascular
disease.3,4
These people reflect patients that doctors
typically see in their daily clinical practice.5
CAROLINA® was led by an academic trial steering committee and Boehringer Ingelheim and Eli Lilly and Company. CAROLINA® is the only DPP-4 inhibitor, active-comparator cardiovascular outcome trial.
About Trajenta
®
(linagliptin)
Trajenta®
is a one dose, once daily DPP-4 inhibitor that provides significant
efficacy in the reduction of blood sugar levels for adults with type 2
diabetes. It can be prescribed for adults with type 2 diabetes
regardless of age, disease duration, ethnicity, body mass index (BMI),
liver and kidney function.2
Trajenta®
has the
lowest kidney excretion rate of all DPP-4 inhibitors.6-9
About our cardiovascular outcome trials
Cardiovascular
outcome trials are highly relevant, as cardiovascular disease is a major
complication and the leading cause of death in type 2 diabetes.
Worldwide, most people with type 2 diabetes die of a cardiovascular
event.10
In 2015, Boehringer Ingelheim and Eli Lilly and
Company announced results from the landmark cardiovascular outcome trial
EMPA-REG OUTCOME®
with the SGLT2 inhibitor, empagliflozin,
which reduced the relative risk of cardiovascular death by 38 percent in
adults with type 2 diabetes and established cardiovascular disease, on
top of standard of care.†‡11-13
As a result, empagliflozin
was the first oral type 2 diabetes medicine to have either a
cardiovascular indication or data on the reduction of the risk of
cardiovascular death included in the label in many countries.11,12
CAROLINA® is one of two cardiovascular outcome trials with the DPP-4 inhibitor, linagliptin.3,4 CAROLINA® and the CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk trial (CARMELINA® )14,15 provide one of the most comprehensive datasets on the long-term safety of a DPP-4-inhibitor.
CARMELINA® is a multi-national, randomised, double-blind, placebo-controlled clinical trial that involved 6,979 adults with type 2 diabetes from 27 countries at more than 600 sites observed for a median duration of 2.2 years.14,15 CARMELINA® studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.14,15 The trial met its primary endpoint,§ with linagliptin demonstrating a similar cardiovascular safety profile compared to placebo when added to standard of care.14 CARMELINA® also included a key secondary composite endpoint,** showing a similar kidney safety profile compared to placebo.14 The overall safety profile of linagliptin in CARMELINA® was consistent with previous data and no new safety signals were observed.2,14 CARMELINA® also showed a similar rate of hospitalisation for heart failure for linagliptin compared to placebo.14
To learn more about CAROLINA® and CARMELINA® , please visit: https://www.carmelinatrial.com/
Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/CAROLINA-full-data
*
Secondary composite efficacy outcome defined as HbA1c at or
below 7 percent at the final visit without rescue medication, moderate
or severe hypoglycaemia or a 2 percent or greater weight gain.
†
Adult patients with type 2 diabetes and coronary artery disease,
peripheral artery disease, or a history of MI or stroke
‡
Standard of care included cardiovascular medications and blood sugar
lowering agents given at the discretion of physicians
§
Primary endpoint defined as time to first occurrence of the 3P-MACE
(cardiovascular death, non-fatal myocardial infarction or non-fatal
stroke)
**
Key secondary endpoint defined as time to
first occurrence of sustained end stage kidney disease (ESKD), death due
to kidney disease, or a sustained decrease in eGFR from baseline of ≥40
percent compared to placebo
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005823/en/
Contact:
Tetsu Owari Media & PR Boehringer Ingelheim Email: press@boehringer-ingelheim.com Phone: +49 (6132) 77 184867
Stephan Thalen Global Business Communications Lilly Diabetes Email: stephan.thalen@lilly.com Phone: +1 317 903 5640
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech and Equinor Expand Digital Collaboration2.7.2025 13:08:00 CEST | Press release
HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e
Wizz Air Tops Major Airline Emissions Rankings2.7.2025 11:00:00 CEST | Press release
Cirium, the aviation analytics company, creates a new transparent standard and ranking for airline CO2 emissions, identifying the best performing airlines in specific categories Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/ The top 20 Major airlines globally, ranked by lowest CO2/ASK Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report. The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments.
L&T Technology Services Chosen by TRATON GROUP as Strategic Engineering Partner in Global R&D Transformation2.7.2025 10:59:00 CEST | Press release
Multi-year collaboration in LTTS’ Mobility segment to drive platform synergies, electrification, and innovation for TRATON GROUP L&T Technology Services (BSE: 540115, NSE: LTTS), today announced that it has been chosen by the TRATON GROUP, one of the world’s leading manufacturers of commercial vehicles, as a strategic engineering partner. This collaboration in LTTS’ Mobility segment will support TRATON’s roadmap to build a unified, future-ready product-development platform that delivers scale, speed, and sustainable mobility solutions worldwide. TRATON is reshaping its global R&D ecosystem to unlock cross-brand synergies while expanding the share of battery-electric vehicles in line with its 2029 profitability and sustainability targets. LTTS’ selection will see the company provide engineering support, from mechanical and software engineering to digital systems integration - across key development hubs in Sweden, Germany, the United States, Poland, and India. The collaboration position
Nexo Becomes First-Ever Digital Wealth Platform of the DP World Tour, Launches Nexo Championship2.7.2025 10:30:00 CEST | Press release
Named Official Digital Wealth Platform of the DP World Tour through 2027 Nexo becomes Title Partner of the Nexo Championship, which takes place at Trump International Golf Links in August 2025 Nexo, the premier digital assets wealth platform, has signed a three-year landmark partnership with the DP World Tour, becoming an Official Marketing Partner and the Tour’s Official Digital Wealth Platform through 2027. This agreement marks the first-ever multi-year partnership between a digital assets company and a major global golf tour — a historic convergence of crypto and golf — reflecting both organizations’ shared commitment to performance, innovation, and a global outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702770847/en/ Nexo becomes the first-ever Official Digital Wealth Platform of the DP World Tour. Nexo has also become the Title Partner of the newly renamed Nexo Championship — previously the Scottish Champion
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta2.7.2025 10:00:00 CEST | Press release
Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle® (follitropin delta); alongside its existing unique algorithm-based dosing Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications.1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 wome
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom